Jing-Yu Chen, Jian-Di Li, Rong-Quan He, Zhi-Guang Huang, Gang Chen, Wen Zou
{"title":"对乳腺癌中磷酸甘油酸激酶 1 的表达及其在三阴性乳腺癌中的明显上调进行文献计量分析。","authors":"Jing-Yu Chen, Jian-Di Li, Rong-Quan He, Zhi-Guang Huang, Gang Chen, Wen Zou","doi":"10.5306/wjco.v15.i7.867","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Phosphoglycerate kinase 1 (PGK1) has been identified as a possible biomarker for breast cancer (BC) and may play a role in the development and advancement of triple-negative BC (TNBC).</p><p><strong>Aim: </strong>To explore the PGK1 and BC research status and PGK1 expression and mechanism differences among TNBC, non-TNBC, and normal breast tissue.</p><p><strong>Methods: </strong>PGK1 and BC related literature was downloaded from Web of Science Core Collection Core Collection. Publication counts, key-word frequency, cooperation networks, and theme trends were analyzed. Normal breast, TNBC, and non-TNBC mRNA data were gathered, and differentially expressed genes obtained. Area under the summary receiver operating characteristic curves, sensitivity and specificity of PGK1 expression were determined. Kaplan Meier revealed PGK1's prognostic implication. PGK1 co-expressed genes were explored, and Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Disease Ontology applied. Protein-protein interaction networks were constructed. Hub genes identified.</p><p><strong>Results: </strong>PGK1 and BC related publications have surged since 2020, with China leading the way. The most frequent keyword was \"Expression\". Collaborative networks were found among co-citations, countries, institutions, and authors. PGK1 expression and BC progression were research hotspots, and PGK1 expression and BC survival were research frontiers. In 16 TNBC <i>vs</i> non-cancerous breast and 15 TNBC <i>vs</i> non-TNBC datasets, PGK1 mRNA levels were higher in 1159 TNBC than 1205 non-cancerous breast cases [standardized mean differences (SMD): 0.85, 95% confidence interval (95%CI): 0.54-1.16, <i>I</i>² = 86%, <i>P</i> < 0.001]. PGK1 expression was higher in 1520 TNBC than 7072 non-TNBC cases (SMD: 0.25, 95%CI: 0.03-0.47, <i>I</i>² = 91%, <i>P</i> = 0.02). Recurrence free survival was lower in PGK1-high-expression than PGK1-low-expression group (hazard ratio: 1.282, <i>P</i> = 0.023). PGK1 co-expressed genes were concentrated in ATP metabolic process, HIF-1 signaling, and glycolysis/gluconeogenesis pathways.</p><p><strong>Conclusion: </strong>PGK1 expression is a research hotspot and frontier direction in the BC field. PGK1 may play a strong role in promoting cancer in TNBC by mediating metabolism and HIF-1 signaling pathways.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"15 7","pages":"867-894"},"PeriodicalIF":2.6000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271732/pdf/","citationCount":"0","resultStr":"{\"title\":\"Bibliometric analysis of phosphoglycerate kinase 1 expression in breast cancer and its distinct upregulation in triple-negative breast cancer.\",\"authors\":\"Jing-Yu Chen, Jian-Di Li, Rong-Quan He, Zhi-Guang Huang, Gang Chen, Wen Zou\",\"doi\":\"10.5306/wjco.v15.i7.867\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Phosphoglycerate kinase 1 (PGK1) has been identified as a possible biomarker for breast cancer (BC) and may play a role in the development and advancement of triple-negative BC (TNBC).</p><p><strong>Aim: </strong>To explore the PGK1 and BC research status and PGK1 expression and mechanism differences among TNBC, non-TNBC, and normal breast tissue.</p><p><strong>Methods: </strong>PGK1 and BC related literature was downloaded from Web of Science Core Collection Core Collection. Publication counts, key-word frequency, cooperation networks, and theme trends were analyzed. Normal breast, TNBC, and non-TNBC mRNA data were gathered, and differentially expressed genes obtained. Area under the summary receiver operating characteristic curves, sensitivity and specificity of PGK1 expression were determined. Kaplan Meier revealed PGK1's prognostic implication. PGK1 co-expressed genes were explored, and Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Disease Ontology applied. Protein-protein interaction networks were constructed. Hub genes identified.</p><p><strong>Results: </strong>PGK1 and BC related publications have surged since 2020, with China leading the way. The most frequent keyword was \\\"Expression\\\". Collaborative networks were found among co-citations, countries, institutions, and authors. PGK1 expression and BC progression were research hotspots, and PGK1 expression and BC survival were research frontiers. In 16 TNBC <i>vs</i> non-cancerous breast and 15 TNBC <i>vs</i> non-TNBC datasets, PGK1 mRNA levels were higher in 1159 TNBC than 1205 non-cancerous breast cases [standardized mean differences (SMD): 0.85, 95% confidence interval (95%CI): 0.54-1.16, <i>I</i>² = 86%, <i>P</i> < 0.001]. PGK1 expression was higher in 1520 TNBC than 7072 non-TNBC cases (SMD: 0.25, 95%CI: 0.03-0.47, <i>I</i>² = 91%, <i>P</i> = 0.02). Recurrence free survival was lower in PGK1-high-expression than PGK1-low-expression group (hazard ratio: 1.282, <i>P</i> = 0.023). PGK1 co-expressed genes were concentrated in ATP metabolic process, HIF-1 signaling, and glycolysis/gluconeogenesis pathways.</p><p><strong>Conclusion: </strong>PGK1 expression is a research hotspot and frontier direction in the BC field. PGK1 may play a strong role in promoting cancer in TNBC by mediating metabolism and HIF-1 signaling pathways.</p>\",\"PeriodicalId\":23802,\"journal\":{\"name\":\"World journal of clinical oncology\",\"volume\":\"15 7\",\"pages\":\"867-894\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271732/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World journal of clinical oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5306/wjco.v15.i7.867\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v15.i7.867","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:目的:探讨PGK1和BC的研究现状,以及PGK1在TNBC、非TNBC和正常乳腺组织中的表达和机制差异:方法:从 Web of Science Core Collection 核心文库下载与 PGK1 和 BC 相关的文献。分析了发表次数、关键词频率、合作网络和主题趋势。收集正常乳腺、TNBC 和非 TNBC mRNA 数据,并获得差异表达基因。确定了 PGK1 表达的受体操作特征曲线下面积、敏感性和特异性。Kaplan Meier揭示了PGK1的预后意义。探索了 PGK1 共表达基因,并应用了基因本体、京都基因和基因组百科全书以及疾病本体。构建了蛋白质-蛋白质相互作用网络。确定了枢纽基因:自 2020 年以来,PGK1 和 BC 相关的论文数量激增,其中中国居首位。最常见的关键词是 "表达"。在共同引用、国家、机构和作者之间发现了合作网络。PGK1表达和BC进展是研究热点,PGK1表达和BC生存是研究前沿。在16个TNBC与非癌乳腺癌数据集和15个TNBC与非TNBC数据集中,1159个TNBC病例的PGK1 mRNA水平高于1205个非癌乳腺癌病例[标准化平均差异(SMD):0.85,95%置信区间(95%CI):0.54-1.16,I² = 86%,P < 0.001]。1520例TNBC患者的PGK1表达高于7072例非TNBC患者(SMD:0.25,95%CI:0.03-0.47,I² = 91%,P = 0.02)。PGK1高表达组的无复发生存率低于PGK1低表达组(危险比:1.282,P = 0.023)。PGK1共表达基因主要集中在ATP代谢过程、HIF-1信号转导和糖酵解/糖元生成途径中:结论:PGK1 的表达是 BC 领域的研究热点和前沿方向。结论:PGK1的表达是BC领域的研究热点和前沿方向,PGK1可能通过介导代谢和HIF-1信号通路在TNBC的促癌过程中发挥重要作用。
Bibliometric analysis of phosphoglycerate kinase 1 expression in breast cancer and its distinct upregulation in triple-negative breast cancer.
Background: Phosphoglycerate kinase 1 (PGK1) has been identified as a possible biomarker for breast cancer (BC) and may play a role in the development and advancement of triple-negative BC (TNBC).
Aim: To explore the PGK1 and BC research status and PGK1 expression and mechanism differences among TNBC, non-TNBC, and normal breast tissue.
Methods: PGK1 and BC related literature was downloaded from Web of Science Core Collection Core Collection. Publication counts, key-word frequency, cooperation networks, and theme trends were analyzed. Normal breast, TNBC, and non-TNBC mRNA data were gathered, and differentially expressed genes obtained. Area under the summary receiver operating characteristic curves, sensitivity and specificity of PGK1 expression were determined. Kaplan Meier revealed PGK1's prognostic implication. PGK1 co-expressed genes were explored, and Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Disease Ontology applied. Protein-protein interaction networks were constructed. Hub genes identified.
Results: PGK1 and BC related publications have surged since 2020, with China leading the way. The most frequent keyword was "Expression". Collaborative networks were found among co-citations, countries, institutions, and authors. PGK1 expression and BC progression were research hotspots, and PGK1 expression and BC survival were research frontiers. In 16 TNBC vs non-cancerous breast and 15 TNBC vs non-TNBC datasets, PGK1 mRNA levels were higher in 1159 TNBC than 1205 non-cancerous breast cases [standardized mean differences (SMD): 0.85, 95% confidence interval (95%CI): 0.54-1.16, I² = 86%, P < 0.001]. PGK1 expression was higher in 1520 TNBC than 7072 non-TNBC cases (SMD: 0.25, 95%CI: 0.03-0.47, I² = 91%, P = 0.02). Recurrence free survival was lower in PGK1-high-expression than PGK1-low-expression group (hazard ratio: 1.282, P = 0.023). PGK1 co-expressed genes were concentrated in ATP metabolic process, HIF-1 signaling, and glycolysis/gluconeogenesis pathways.
Conclusion: PGK1 expression is a research hotspot and frontier direction in the BC field. PGK1 may play a strong role in promoting cancer in TNBC by mediating metabolism and HIF-1 signaling pathways.
期刊介绍:
The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.